Effectiveness of COVID-19 mRNA vaccine booster dose relative to primary series during a period of Omicron circulation
Petrie, J. G.; King, J. P.; McClure, D. L.; Rolfes, M. A.; Meece, J. K.; Belongia, E. A.; McLean, H. Q.
Show abstract
During a period of Omicron variant circulation, we estimated relative VE of COVID-19 mRNA booster vaccination versus primary two-dose series in an ongoing community cohort. Relative VE was 66% (95% CI: 46%, 79%) favoring the booster dose compared to primary series vaccination. Our results support current booster recommendations.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effectiveness of second booster compared to first booster and protection conferred by previous SARS CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France 96%
- Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting 96%
- Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥65 years in the United States 96%
Similar papers in this journal
- Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine 96%
- Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study 96%
- Vaccine effectiveness of CanSino (Adv5-nCoV) COVID-19 vaccine among childcare workers – Mexico, March–December 2021 96%
Similar papers in this journal
- Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide Danish cohort study 95%
- Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): a randomized, observer-blinded, placebo-controlled trial 95%
- Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults 95%
Similar papers in this journal
- Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against 1 JN.1 Subvariants in Adult Participants 96%
- Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine 96%
- Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysis 95%
Similar papers in this journal
- Post-vaccination neutralization responses to Omicron sub-variants 95%
- Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial 95%
- Safety and immunogenicity of a heterologous booster of protein subunit vaccine MVC-COV1901 after two doses of adenoviral vector vaccine AZD1222 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.